AU2014100709A4 - In Vitro Anti-influenza Virus Activities of a New Lignan Glycoside from the Latex of Calotropis gigantea - Google Patents
In Vitro Anti-influenza Virus Activities of a New Lignan Glycoside from the Latex of Calotropis gigantea Download PDFInfo
- Publication number
- AU2014100709A4 AU2014100709A4 AU2014100709A AU2014100709A AU2014100709A4 AU 2014100709 A4 AU2014100709 A4 AU 2014100709A4 AU 2014100709 A AU2014100709 A AU 2014100709A AU 2014100709 A AU2014100709 A AU 2014100709A AU 2014100709 A4 AU2014100709 A4 AU 2014100709A4
- Authority
- AU
- Australia
- Prior art keywords
- compound
- influenza
- lignan glycoside
- meoh
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 34
- -1 Lignan Glycoside Chemical class 0.000 title claims abstract description 25
- 229930182470 glycoside Natural products 0.000 title claims abstract description 24
- 229930013686 lignan Natural products 0.000 title claims abstract description 23
- 235000009408 lignans Nutrition 0.000 title claims abstract description 23
- 239000004816 latex Substances 0.000 title claims abstract description 11
- 229920000126 latex Polymers 0.000 title claims abstract description 11
- 241000208250 Calotropis gigantea Species 0.000 title claims abstract 3
- 230000000694 effects Effects 0.000 title abstract description 24
- 241000700605 Viruses Species 0.000 title abstract description 23
- 238000000338 in vitro Methods 0.000 title abstract description 9
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 claims abstract description 13
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-Pinoresinol Natural products C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 claims abstract description 13
- HGXBRUKMWQGOIE-NSMLZSOPSA-N (-)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-NSMLZSOPSA-N 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 241000712461 unidentified influenza virus Species 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 208000037797 influenza A Diseases 0.000 claims description 12
- 235000019439 ethyl acetate Nutrition 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003643 water by type Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 208000037798 influenza B Diseases 0.000 claims description 4
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 229940125904 compound 1 Drugs 0.000 description 46
- 238000004440 column chromatography Methods 0.000 description 16
- 230000000120 cytopathologic effect Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 241001247986 Calotropis procera Species 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 10
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 10
- 241000193096 Human adenovirus B3 Species 0.000 description 9
- 241000725643 Respiratory syncytial virus Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 241000272525 Anas platyrhynchos Species 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 6
- 102100032442 Protein S100-A8 Human genes 0.000 description 6
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 229960000329 ribavirin Drugs 0.000 description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 235000014676 Phragmites communis Nutrition 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000005640 glucopyranosyl group Chemical group 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000252870 H3N2 subtype Species 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 238000005100 correlation spectroscopy Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- VJOBNGRIBLNUKN-BMHXQBNDSA-N (-)-medioresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 VJOBNGRIBLNUKN-BMHXQBNDSA-N 0.000 description 2
- JUWPDDCLNHOUNO-GQUPQBGVSA-N 6'-O-vanilloylisotachioside Natural products COc1cc(ccc1O)C(=O)OC[C@H]2O[C@@H](Oc3ccc(O)cc3OC)[C@H](O)[C@@H](O)[C@@H]2O JUWPDDCLNHOUNO-GQUPQBGVSA-N 0.000 description 2
- 241000208327 Apocynaceae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000208267 Calotropis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000018265 Virus Receptors Human genes 0.000 description 2
- 108010066342 Virus Receptors Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BVWTXUYLKBHMOX-UHFFFAOYSA-N methyl vanillate Chemical compound COC(=O)C1=CC=C(O)C(OC)=C1 BVWTXUYLKBHMOX-UHFFFAOYSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VJOBNGRIBLNUKN-UHFFFAOYSA-N (+)-medioresinal Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 VJOBNGRIBLNUKN-UHFFFAOYSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- MLOLGZQVRYQQKK-UHFFFAOYSA-N 1-hydroxy-2-[(2-hydroxy-5-methoxyphenyl)methylideneamino]guanidine 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.COC1=CC=C(O)C(C=NNC(=N)NO)=C1 MLOLGZQVRYQQKK-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000001026 1H--1H correlation spectroscopy Methods 0.000 description 1
- 238000012584 2D NMR experiment Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UEIWCDIFYPMJSO-GQUPQBGVSA-N 6'-O-vanilloyltachioside Natural products C1=C(O)C(OC)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=3C=C(OC)C(O)=CC=3)O2)O)=C1 UEIWCDIFYPMJSO-GQUPQBGVSA-N 0.000 description 1
- 241000983387 Adenium obesum Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000009535 CYSTUS052 Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 101150047505 FIM1 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000134304 Influenza A virus H3N2 Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 230000005723 MEK inhibition Effects 0.000 description 1
- 240000009200 Macaranga tanarius Species 0.000 description 1
- 235000000487 Macaranga tanarius Nutrition 0.000 description 1
- 229930182415 Macarangioside Natural products 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 244000087803 Parsonsia laevigata Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 240000005049 Prunus salicina Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 244000236580 Psidium pyriferum Species 0.000 description 1
- 235000013929 Psidium pyriferum Nutrition 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- SGSXWFDMRKAVLS-UHFFFAOYSA-N [6'-acetyloxy-5-[3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propylcarbamoyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl] acetate Chemical compound C1=C(C=2C(NC(=O)C=2C=2C3=CC=CC=C3N(C)C=2)=O)C2=CC=CC=C2N1CCCNC(=O)C(C=C1C(=O)O2)=CC=C1C12C2=CC=C(OC(C)=O)C=C2OC2=CC(OC(=O)C)=CC=C12 SGSXWFDMRKAVLS-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001738 cardenolides Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 201000006599 congenital myasthenic syndrome 4C Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 208000037802 influenza A (H3N2) Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 235000009018 li Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008779 ma-xing-shi-gan-tang Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
In Vitro Anti-influenza Virus Activities of a New Lignan Glycoside from the Latex of Calotropis gigantea The present invention provides a novel lignan glycoside compound represented by formula (I) and the use thereof as an anti-influenza agent. A method of treating influenza comprising administering an effective amount of a lignan glycoside compound to a subject in need thereof is also provided. The lignan glycoside compound comprises at least one vanilloyl moiety. Further, a method of isolating (+)-pinoresinol 4-0-[6"-0 vanilloyl]-p8-D-glucopyranosideas as represented by formula (III) is also provided. <DocRef#00125742-RM > M006.03 1.DRF 24 Spec draft v.1
Description
In Vitro Anti-influenza Virus Activities of a New Lignan Glycoside from the Latex of Calotropis gigantea CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application having Serial No. 61/923,229 filed Jan 3, 2014, which is hereby incorporated by reference herein in its entirety. FIELD OF INVENTION [0002] This invention relates to novel lignan glycoside and the use thereof as an anti influenza agent. BACKGROUND OF INVENTION [0003] Influenza virus causes many upper respiratory tract infection diseases. It is transmitted easily from person to person via air and spreads rapidly in seasonal epidemics causing numerous people death from severe complications in pandemic years worldwide as reported by World Health Organization (WHO) in 2013. The latest global pandemic caused by HINI virus, characterized by a unique triple-reassortant gene segments of bird, swine and human influenza viruses, has resulted in more than 18,000 human deaths since its appearance in April 2009. More recently, the new avian-origin influenza A (H7N9) virus has caused 111 cases of human infection in China as of May 10, 2013 (Gao H.N., et al. 2013), and some of the patients have died from severe pneumonia brought on by this virus. Moreover, the rate of emergence of viruses resistant to available antiviral drugs including M2 blockers (such as amantadine and rimantadine) and neuraminidase (NA) inhibitors (such as oseltamivir and zanamivir) has been increasing globally and greatly decreasing their effectiveness (Du J. et al., 2012; Deyde V. M. et al., 2007). It is urgently needed to develop safe and effective new antiviral drugs to combat viral infection either for therapeutic or prophylactic purposes. 1 M006.03 1.DRF Spec As Filed SUMMARY OF INVENTION [0004] In the light of the foregoing background, many researchers have tried and keep trying to find new effective antiviral remedies, especially, from the natural resources. (Yingsakmongkon S. et al., 2008; Sriwilaijareon N. et al., 2012; Kiyohara H., et al., 2012), and it is an object of the present invention to provide an alternate antiviral drug. [0005] Accordingly, the present invention, in one aspect, is a lignan glycoside compound represented by formula (I). OR HO H H OH ONe (I) [0006] In an exemplary embodiment of the present invention, in the lignan glycoside compound of formula (I), R is represented by vanilloyl group represented by formula (II), and the resulting compound is (+)-pinoresinol 4-0-[6"-O-vanilloyl]-#-D-glucopyranoside and represented by formula (III). 0OH M0. OM2 o (II) M006.031.DRF 2 Spec draft v.1 OH 4 e OM HO 5,.40 HH OH (III) [0007] In another exemplary embodiment, in the lignan glycoside compound of formula (I), R is represented by H; said compound is (+)-pinoresinol 4-O-p-D-gluco-pyranoside. [0008] According to another aspect of the present invention, a method of treating influenza comprising administering an effective amount of a lignan glycoside compound to a subject in need thereof The lignan glycoside compound comprises at least one vanilloyl moiety. [0009] In an exemplary embodiment, the lignan glycoside compound is (+)-pinoresinol 4-O-[6"-O-vanilloyl]-p8-D-glucopyranosideas as represented by formula (III). In a further exemplary embodiment, the influenza is caused by an influenza virus selected from a group consisting of influenza A strain A/Aichi/2/68, influenza A strain A/PR/8/34, influenza A strain A/FM/1/47 and influenza B strain Inf B/Lee/i 940. [0010] In a further aspect of the present invention, a method of isolating (+)-pinoresinol 4-O-[6"-O-vanilloyl]-p8-D-glucopyranosideas as represented by formula (III) comprising the steps of: [0011] (a) adding 95% ethanol to latex of Calotropis gigantea produce a filterable precipitate mixture; [0012] (b) the mixture was then sonicated at room temperature then centrifuged; M006.03 1.DRF 3 Spec draft v.1 [0013] (c) the supernatant from the centrifuge product of step (b) was evaporated under reduced pressure to obtain a light yellowish residue; [0014] (d) the residue was suspended in H 2 0 and subjected to liquid-liquid partition by adding EtOAc; [0015] (e) the residue of EtOAc layer was subjected to silica gel CC eluted with the gradient system of CHCl 3 -MeOH-H 2 0 to obtain four fractions of Fr. 1 to Fr.4; [0016] (f) the third fraction, Fr.3, from step (e) was chromatographed over MCI-gel CHP 20P CC eluted with aqueous MeOH to obtain six sub-fractions of Fr.3-1 to Fr.3-6; [0017] (g) the fourth sub-fraction, Fr.3-4, from step (f) was loaded to Bondapak Waters® ODS CC using the gradient of MeOH-H 2 0 to obtain seven sub-fractions of Fr.3-4-1 to Fr.3-4-7; [0018] (h) the fifth sub-fraction, Fr.3-4-5, from step (g) was purified by Silica gel 60 CC eluted with the gradient system of CHCl 3 -MeOH-H 2 0 to obtain eleven sub-fractions of Fr.3-4-5-1 to Fr.3-4-5-11; and [0019] (i) the fifth sub-fraction, Fr.3-4-5-5, from step (h) was further purified by MCI-gel CHP 20P CC using aqueous MeOH to obtain said compound. BRIEF DESCRIPTION OF FIGURES [0020] Fig. 1A shows the chemical structure of Compound 1 and Fig. 1B shows the key HMBC (H to C) and 1
H-
1 H COSY correlations of compound 1. [0021] Fig. 2 shows the chemical structures of Compounds 1-5. [0022] Fig. 3 shows the mild alkaline hydrolysis of Compound 1. [0023] Figs. 4A and 4B respectively illustrates the UHIPLC chromatograms and the MS spectra of Compound 1, (+)-pinoresinol-4-O-p8-D-glucopyranoside (Compound 4) and the compounds from the reaction mixture. M006.03 1.DRF 4 Spec draft v.1 [0024] Fig. 5 shows the IC 50 (tM) of Compound 1 and ribavirin against human influenza viruses. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0025] As used herein and in the claims, "comprising" means including the following elements but not excluding others. [0026] Calotropis gigantea (Asclepiadaceae) is a shrub common in Eastern Asia and Southeast Asia. The barks of this plant are used traditionally in Chinese folk medicine for the treatments of neurodermatitis and syphilis while the leaves are used as a poultice (FOC., 2013). The latex of this plant has been used as an insecticidal agent (Bhaskara and Seshadri, 1943), and as a purgative and a local irritant in indigenous medicine in India (Pari K. et al., 1998). A fascinating series of bioactive secondary metabolites, e.g., cardiotonic steroids, triterpene alcohols, alkaloids and flavonoids has been isolated from different parts of Calotropis plants and showed various pharmacological properties such as analgesic, hepatoprotective, sedative, anti-inflammatory, anti-diarrheal, anti-asthmatic and anticancer activities (Pari K. et al., 1998; Lhinhatrakul and Sutthivaiyakit, 2006; Silva M. C. C. et al., 2010). In this present study, we successfully isolated a new lignan glycoside (Compound 1), together with two known phenolic compounds (Compounds 2 and 3) from the latex of Calotropis gigantea for the first time. Their isolation, structural elucidation and in vitro anti-influenza virus activities were discussed in this application. [0027] The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof [0028] 1. Materials and Methods [0029] 1.1 General experimental procedures [0030] Optical rotation was measured on Rudolph Autopol I automatic polarimeter (USA). UV spectrum was performed on a Beckman Coulter DU800 spectrophotometer M006.03 1.DRF 5 Spec draft v.1 (USA). IR spectrum was obtained on a PerkinElmer Spectrum One Fourier transform infrared (FTIR) spectrometer (KBr). The 1H, 1C and 2D NMR experiments were conducted on a Bruker Ascend® 600 NMR spectrometer (600 MHz for 1H and 150 MHz for 13 C) using the chemical shifts of CD 3 0D ( 1 H, 6H = 3.310; 13 C, 6C = 49.150) as the references. Chemical shifts were expressed in 6 (ppm) and coupling constants ( J ) are given in Hz. ESI-TOF-MS spectra were measured on an Agilent 6230 Accurate mass Time-of-Flight (TOF) mass spectrometer (USA). UHIPLC analyses were carried out on an Agilent Technologies 1290 Infinity liquid chromatography system using an ACQUITY UPLC BEH C 18 column (1.7 ptm, 2.1 x 100 mm, Waters*, Ireland). HPLC analysis was done on an Agilent 1100 series HPLC system using an Alltima* C 18 column (5p.im, 4.6 x 250 mm, Alltech, Grace, USA). Preparative HPLC was conducted on LabAlliance with VisionHT* C 18 Polar column (5p.m, 22 x 250 mm, Grace, USA). Medium Pressure Liquid Chromatography (MPLC, Sepacore, Buchi, Switzerland) was done using a Siliabond* C 18 ODS (40-63 ptm, Silicycle, Canada) column (36 x 460 mm). Column chromatographies (CC) were performed using silica gel (40-63 ptm, Grace, USA), silica gel 60 (50-55p.m, Merck, Germany), MCI-gel CHIP 20P (75-150p.m, Mitsubishi Chemical Co. Ltd., Japan) and Bondapak Waters® ODS (55-105 ptm, Waters, USA). Thin-layer chromatography (TLC) was conducted on pre-coated HPTLC, TLC Kieselgel 60 F 25 4 plates or TLC silica gel 60 RP-18 F 2 5 4 s (200 pim thick, Merck KGaA, Germany) and the spots were visualized under ultraviolet light (UV, wavelength 254 nm) and by spraying with 5% sulfuric acid in 95% EtOH, followed by heating at 110 C. [0031] 1.2. Reagents and compounds [0032] Absolute ethanol (AR grade) was purchased from Merck (Germany). Chloroform and ethyl acetate (AR grade) were bought from RCI Labscan Limited (Bangkok, Thailand). Methanol and acetronitrile (HPLC grade) were purchased from Tedia (USA).
CD
3 0D was purchased from Sigma Aldrich (USA). Sodium methoxide was a product of Sigma-Aldrich (USA). The purities of all isolated compounds for bioassay were more than 95% determined by UIHPLC analysis. [0033] 1.3. Plant material M006.03 1.DRF 6 Spec draft v.1 [0034] The latex of Calotropis gigantea (CGLA) was collected in Lampang, Thailand, during the period between August and October 2011. It was preserved by adding 10% EtOH and then kept in -40 C freezer. The frozen CGLA was defrozen overnight at 4'C, and was allowed to stand at room temperature for 2 h before isolation. The herbarium specimen was from a shrub. A voucher specimen (No. SKLO07) was deposited at State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology. [003 5] 1.4. Extraction and isolation [0036] 95% ethanol was added to CGLA (1 L) to produce a filterable precipitate (Bhaskara and Seshadri, 1943). The mixture was sonicated at room temperature and then centrifuged. The supernatant was evaporated under reduced pressure to result in a light yellowish residue (85.5 g). The residue was suspended in H 2 0 and then subjected to liquid-liquid partition by adding EtOAc. The residue (6.3 g) of EtOAc layer was subjected to silica gel CC eluted with the gradient system of CHCl 3 -MeOH-H 2 0 (from 10:0:0 to 6:4:1) to obtain 4 fractions (Fr.1 to 4). Fr.3 (1.2 g) was chromatographed over MCI-gel CHIP 20P CC eluted with aqueous MeOH (30 % to 100%) to obtain 6 fractions (Fr.3-1 to Fr.3-6). Fr.3-4 (300 mg) was loaded to Bondapak Waters® ODS CC using the gradient of MeOH-H 2 0 (50:50 to 100:0) to give 7 fractions (Fr.3-4-1 to Fr.3-4-7). Fr.3-4 5 (76.8 mg) was purified by silica gel 60 CC eluted with the gradient system of CHCl 3 MeOH-H 2 0 (from 10:0:0 to 7:3:0.5) to obtain 11 fractions (Fr.3-4-5-1 to Fr.3-4-5-11). Finally, Fr.3-4-5-5 (20.1 mg) was further purified by MCI-gel CHiP 20P CC using aqueous MeOH (30 % - 100 %) to yield Compound 1 (5.0 mg) eluted at 80% aqueous MeOH. [0037] Fr.4 (0.7 g) was separated by MCI-gel CHP 20P CC eluted with MeOH-H 2 0 (50:50 to 100:0) to obtain 13 fractions (Fr4-1 to Fr4-13). Fr.4-3 (67mg) was subjected to silica gel 60 CC eluted with the gradient of CHCl 3 -MeOH-H 2 0 (from 10:0:0 to 7:3:0.5) to give 3 fractions (Fr.4-1 to Fr.4-3). Fr.4-2 (8 mg) was further purified by preparative HPLC using 35% aqueous MeOH isocratic as a mobile phase to afford Compound 2 (2 mg) and Compound 3 (3 mg). M006.03 1.DRF 7 Spec draft v.1 [0038] To obtain Compound 1 in a larger amount, CGLA (3 L) was isolated with similar protocols of 1L-CGLA isolation to obtain EtOH total extract and the residue from EtOAc layer 240.0 g and 20.7 g, respectively. The residue of EtOAc layer (20.7 mg) was further subjected over silica gel CC eluted with the gradient of CHCl 3 -MeOH-H 2 0 (10:0:0 to 6:4:1) to obtain 8 fractions (Fr.A to H). Fr G (3.0 g) was purified by MPLC C 18 Siliabond* ODS eluted within one hour by using 20-80% MeOH in water as a mobile phase to obtain 7 fractions (Fr.G1 to Fr.G7). Fr.G6 (2.0 g) was purified by MPLC again using the gradient system of 30-60% aqueous MeOH eluted within 60 minutes to furnish 3 fractions (Fr.G6-1 to Fr.G6-3). Fr. G6-1 (659 mg) was further purified by MPLC using 40-60% aqueous MeOH to elute within 60 minutes to furnish Compound 1 (127 mg). [0039] 1.5. Mild alkaline hydrolysis of Compound 1 [0040] A solution of Compound 1 (0.2 mg, 0.3 ptmol) in MeOH (1 ml) was hydrolyzed with sodium methoxide (NaOMe, 1.6 mg, 30 ptmol) for 48 h at room temperature (r.t.) and the hydrolysis reaction is illustrated in Fig. 3. The chemical reaction was terminated by adding formic acid after two products, Compounds la and lb (the formulae of Compounds la and lb are shown in Fig. 3) were clearly detected by TLC analysis. The reaction mixture was then subjected to UHPLC/ ESI-TOF-MS (positive mode) analysis to confirm reaction products of Compounds la and lb (Fig. 4). Compound la was identified by comparing its UHIPLC retention time (6.862 min) and ESI-TOF-MS data ([M+Na]f at m z 543.1830 and [M+NH 4 ]f at m z 538.2274) with those of the reference compound (+)-pinoresinol-4-O-p8-D-glucopyranoside (Compound 4) (retention time at 6.858 min, ESI-TOF-MS data of [M+Na]f at m z 543.1835 and [M+NH4]f at m z 538.2299, calculated for C 2 6
H
32 0 1 Na, [M+Na]f at m z 543.1837 and [M+NH4]f at m z 538.2283) while Compound lb was identified as methyl ester of 4-hydroxy-3-methoxy benzoic acid by its accurate mass ([M+H]f at m z 183.0654, calculated for C 9 HioO 4 Na, [M+H]f at m z 183.0652). [0041] 1.6. Characterization data [0042] Compound 1 : (+)-pinoresinol 4-0-[6"-O-vanilloyl]-p-D-glucopyranoside, a light brown powder; [U]2 5 D +16.48 (c 0.100, MeOH); IR (KBr): vmn. = cm 1 3405, 1705, 1598 M006.03 1.DRF 8 Spec draft v.1 and 1515 cm 1 ; UV(MeOH): mx, nm (log , ) = 221 (4.60) and 266 (4.22); for 13C and H NNMR (CD 3 0D) spectroscopic data (see Table 1 below for details of the data). ESI-TOF MS (positive mode) found [M+Na]f at m z 693.2150 (Calculated for C 34
H
38
O
14 Na at m z 693.2154). Table 1 H (600 MHz) and C (150 MVIHz) NIR spectroscopic data (in CD 3 OD) for Compound 1 Compound 1 Moiety Position oc P( Jin Hz) HMBC (H to C) COSY (H to H) Aglycone moiety 1 137.3 2 111.6 6.97(s) 1,4,6,7 6 3 150.6 4 147.1 5 117.6 6.98 (d, 8.4) 1, 3,4 6 6 119.2 6.46 (dd, 8.4,1.8) 2,4,7 2,5 7 87.0 4.70 (d, 5.4) 1, 2, 6, 8, 9' 8 8 55.4 3.01 (m) 1,8' 7, 9, 8' 9 72.8 4.27 (dd, 9.0,7.2) 7, 8 8, 9 3.83 (m) 8, 7' 8,9 3-OMe 56.7 3.86 (s) 3 1' 133.7 2' 111.0 7.00 (d, 1.8) 4', 6', 7' 6' 3' 149.1 4' 147.3 5' 116.0 6.80 (d, 7.8) 1', 3' 6' 6' 120.2 6.85 (dd, 7.8,1.8) 7, 2', 4', 7' 2', 5' 7' 87.6 4.69 (d, 5.4) 1', 2', 6' 8' 8' 55.3 3.11 (m) 7, 8, 1' 8, 7', 9' 9' 72.5 4.15 (dd, 9.0,6.6) 7' 8', 9' 3.87 (m) 7, 8' 8', 9' 3-OMe 56.4 3.90(s) 3' Sugar moiety 1" 102.4 4.88 (d, 7.2) 4 2" 2" 74.8 3.54 (m) 1", 3" 1", 3"1 3"1 77.8 3.53 (m) 2", 4" 2", 4" 4" 72.2 3.43 (t, 8.4) 3", 5" 3", 5" 5" 75.6 3.79 (m) 4", 6" 4", 6" 6" 65.0 4.65 (dd, 11.7,1.8) 7"' 5", 6" 4.49 (dd, 11.7, 7.8) 5", 7"' 5", 6" Vanilloyl moiety 1"' 122.5 2"' 113.8 7.56 (d, 1.8) 1"', 3"', 4"', 6"', 7"' 6"' 3"' 148.8 M006.03 1.DRF 9 Spec draft v.1 4"' 153.1 5"' 116.0 6.90 (d, 8.4) 1"', 3"', 4"' 6"' 6"' 125.3 7.61 (dd, 8.4,1.8) 2"', 4"', 7"' 2"', 5"' 7"' 167.7 3"'-OMe 56.5 3.86 (s) 3"' [0043 ] 1.7. Cells and virus strains [0044] Madin Darby Canine Kidney (MDCK), and HEp-2 cells were purchased from the American Tissue Culture Collection (ATCC). Influenza virus A/PR/8/34(H1N1), A/FM/1/47(H1N1), seasonal influenza A/Aichi/2/68 (H3N2) and respiratory syncytial virus (RSV; long strain) were purchased from ATCC. Influenza virus Inf B/Lee/i 940 and adenovirus type 3 (ADV3) were isolated from routine clinical specimens. Avian influenza strains of H6N2 (A/Duck/Guangdong/2009), H7N3 (A/Duck/Guangdong/1994) and H9N2 (A/Chicken/Guangdong/1996) were obtained from Dr. Chen Jianxin who is the professor of South China Agriculture University. The influenza viruses were propagated and passaged in MDCK cells. HEp-2 cells were used as the hosts for both RSV and ADV3. All the cells were grown in Dulbecco's Modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). [0045] 1.8. Cytotoxicity assay [0046] MDCK or HEp-2 cells were seeded into 96-well plate at density of 2 x 104 cells/well (100 ptL), and cultured to reach 90 % confluence at 37 'C under 5 % CO 2 for 24 h. The medium was replaced with the one containing various concentrations of the tested compounds and the cells were further incubated at 37 0 C for 48 h. The cell viability was then determined with the MTT assay as reported (Ehrhardt et al., 2007). The 50% toxic concentration (TC 5 o) was calculated by Reed-Muench analysis (Reed and Muench., 1938). The negative control was cells only and the blank control was the reagent used. [0047] 1.9. Cytopathic effect inhibition assay [0048] MDCK cells (2 x 104) were seeded into 96-well plastic plates and cultured at 37 0 C under 5 % CO 2 for 24 h. For the anti-influenza activity assay, MDCK cells were M006.03 1.DRF 10 Spec draft v.1 inoculated with serial influenza virus strains at 1 00TCID 50 at 37'C for 2 h, followed by removal of the medium and addition of the tested compounds (100 piL) with desired concentrations in serum-free Minimum Essential Medium supplemented with 2 pig/ml of TPCK-trypsin. After incubation for 48 h at 37 0 C, the CPE induced by the influenza virus was measured microscopically (Hsieh C.F. et al., 2012). The concentration required for 50% inhibition (IC 50 ) of the virus-induced CPE was calculated by the Reed-Muench analysis (Reed and Muench., 1938). The data of Compound 1 was further confirmed by MTT assay, and the resulting spectrophotometric data was used to calculate the IC 50 values (Ehrhardt et al., 2007). All data reported was an average from the values of three independent experiments. Selection index (SI) was calculated by the ratio of TC 50 / IC 50 (Yingsakmongkon et al., 2008). [0049] 1.10. Activities against respiratory syncytial virus and adenovirus type 3 [0050] The antiviral activities of Compound 1 against RSV (Graham et al., 1988) and ADV3 (Hui et al., 1994) were evaluated by using CPE inhibition assay on HEp-2 cells. A total of 100 TCID50 (50% tissue culture infective dose) of the viral infective titer was allowed to adsorb to the appropriate confluent HEp-2 cell lines for 1 h, followed by washing of virus with serum free medium. Then, the test medium containing the desired concentrations of Compound 1 was added. After appropriate periods (three to five days) of incubation, the CPE in the virus-infected cells was observed microscopically, and the
IC
50 values were determined by the method of Reed and Muench (Reed and Muench, 1938). [0051] 2. Results and discussion [0052] 2.1. Isolation, purification and structure elucidation of Compound 1 [0053] CGLA (1 L) was precipitated with 95 % EtOH at the ratio of latex: EtOH of 6:4 at room temperature to give alcoholic solution and coagulum. Alcoholic solution was evaporated under reduced pressure before subjected to liquid-liquid partition by H 2 0 EtOAc. The EtOAc layer extract was subjected to a series of separation including normal and reverse phase open column chromatographies and preparative HPLC to give one new M006.03 1.DRF 11 Spec draft v.1 lignan glycoside (Compound 1) and two known phenolic glycosides (Compounds 2 and 3). Three liters of CGLA were further purified with similar protocol of 1 L to obtain Compound 1 (127 mg). [0054] Compound 1 was obtained as a light brown powder and the chemical structure thereof was represented by formula (III) or Fig. 1A. Its molecular formula of C 34
H
38 0 14 was established by the observation of [M+Na]f at m z 693.2150 (calculated [M+Na]f at m z 693.2154) in the positive ESI-TOF-MS as shown in Fig. 4B. The IR spectrum indicated the existence of hydroxyl groups (3405 cm- 1 ), carbonyl group (1705 cm- 1 ) and aromatic rings (1598 and 1515 cm- 1 ). Its UV spectrum supported the presence of aromatic rings (221 nm, log , = 4.60 and 266 nm, log , = 4.22). [0055] The 1 H-NMR spectrum of Compound 1 (as shown in Table 1) displayed signals of three ABX benzene rings, an anomeric, three methoxyls, two oxygenated methylene and two oxygenated methines. The 1C-NMR spectrum showed existence of three benzene rings, an ester carbonyl, a $l-glucopyranosyl moiety and three methoxyl groups. [0056] The presence of characteristic proton and carbon signals of two ABX benzene rings, two methoxy groups, two oxygenated methylene, two oxygenated methines and a $l-glucopyranosyl was closely related to those previously reported for Compound 4 (Deyama T. et al., 1983) except for the presence of typical proton and carbon signals for one more set of ABX benzene ring and a methoxy group together with an ester carbonyl which was in good agreement with the reported values of a vanilloyl moiety (Yang et al., 2007). All these signals suggested the existence of a moiety of Compound 4 and a vanilloyl group in Compound 1. [0057] The 1H-1H COSY spectrum (as shown in Fig. IB) exhibited the correlations of typical proton signals of ABX benzene rings, i.e., the correlations of H-6 to H-2 and H-5 and H-6' to H-2' and H-5' , along with the correlations of characteristic resonances for two fused tetrahydrofuran moiety, i.e., the correlations of two aliphatic methines (H-8 and H-8') to two oxygenated methines (H-7 and H-7') and two oxygenated methylenes (H-9 and H-9'). Moreover, an anomeric proton (6H 4.65, d, J = 7.2 Hz, H-i") of a glucopyranosyl group showed HMBC correlations to C-4 (6c 147.1), suggesting the M006.03 1.DRF 12 Spec draft v.1 linkage of glucopyranosyl to C-4 of aglycone moiety. The large coupling constant at J = 7.2 Hz indicated the pl anomeric configuration in glucopyranosyl moiety. These evidences strongly confirmed the presence of Compound 4 within Compound 1. In addition, the correlations of H-6"' to H-2"' and H-5"' in the IH-IH COSY spectrum and HNMBC correlation between H-6"' (6H 7.61, dd, J = 8.4, 1.8 Hz) to an ester carbonyl at C-7"' (6c 167.7) confirmed the existence of a vanilloyl group in Compound 1. [0058] An alkaline hydrolysis reaction (as illustrated in Fig. 3) of Compound 1 was performed to yield two products Compound la and Compound 1b. Compound la was identified as (+)-pinoresinol 4-0-p8-D glucopyranoside by comparison of its retention time and m z with Compound 4, as illustrated in Fig. 4. Compound lb at retention time of 6.172 min showed [M+H]Tat m z 183.0654 corresponded to methyl ester of 4-hydroxy-3 methoxy benzoic acid (calculated for C 9
H
1 oO 4 Na, [M+H]f at m z 183.0652). [0059] Furthermore, the evidence of downfield shift of C-6" at glucopyranosyl moiety from 6c 60.7 in (+)-pinoresinol 4-0-p8-D-glucopyranoside, Compound 4, (Deyama T. et al., 1983) to 6c 65.0 in Compound 1 indicated the attachment of a vanilloyl group to C-6" of sugar part with similar characteristic reported for Compound 5 (Matsunami K. et al., 2009). This linkage was further confirmed by the HNBC correlations from H-6" (6H 4.65 and 4.49) to C-7"' (6c 167.7) (Table 1, Fig. 1B). Therefore, the structure of Compound 1 was assigned and was named (+)-pinoresinol 4-0-[6"-O-vanilloyl]-p-D-glucopyranoside. [0060] 2.2 Identification of Compounds 2 and 3 [0061] Two known compounds, Compounds 2 and 3, have the same molecular formula of C 2 1
H
2 4 0 11 by the evidence from positive ESI-TOF-MS ([M+Na]f at m z 475.1215 and 475.1217, respectively, calculated [M+Na]f at m z 475.1211). The 'H- and "C-NMR data of Compounds 2 and 3 (see Table 2 for detail of data) showed the presence of one pl glucopyranosyl unit, a vanilloyl moiety which were in good agreement with those reported in literature (Yang X.W. et al., 2007). Compound 2 and 3 were characterized as 6'-O-vanilloyltachioside and 6'-O-vanilloylisotachioside, respectively. Table 2 M006.03 1.DRF 13 Spec draft v.1 H (600 MHz) and C (150 MVIHz) NIR spectroscopic data (in CD 3 OD) for Compounds 2 and 3 Position Compound 2 Compound 3 P C 6H(JinHz) 6C 6H(JinHz) Aglycone moiety 1 152.7 141.0 2 104.2 6.70 (s) 152.3 a 3 149.1 101.9 6.43 (d, 2.7) 4 143.3 155.1 5 116.0 6.56 (d, 8.8) 107.6 6.11 (dd, 8.7, 2.7) 6 110.2 6.55 (d, 7.4) 120.7 6.93 (d, 8.7) 3-OMe 56.6 3.70 (s) 56.6 3.78 (s) Sugar moiety 1' 103.8 4.76 (d, 7.6) 104.3 4.71 (d, 7.6) 2' 75.1 3.45-3.50 (m) 75.2 3.46-3.48 (m) 3' 78.0 3.45-3.50 (m) 77.9 3.46-3.48 (m) 4' 72.2 3.45-3.50 (m) 72.2 3.41 (m) 5' 75.8 3.73 (m) 75.8 3.66 (m) 6' 65.3 4.70 (dd, 11.8, 1.9) 65.2 4.66 (dd, 11.7, 2.1) 4.37 (dd, 11.8, 7.4) 4.36 (dd, 11.7, 7.4) Vanilloyl moiety 1" 122.1 122.5 2" 113.7 7.53 (d, 1.7) 113.8 7.53 (d, 1.8) a 3" 149.3 148.9 4" 153.9 152.3 b 5" 116.3 6.85 (d, 8.3) 116.1 6.86 (d, 8.2) 6" 125.5 7.57 (dd, 8.3, 1.8) 125.4 7.55 (dd, 8.3, 1.8) 7" 168.1 168.0 3"-OMe 56.4 3.85 (s) 56.6 3.86 (s) a c to Assigmnents may be interchanged within each column [0062] 2.3 In vitro anti-influenza virus activity of Compounds 1-4 against A PR 8 34 (HJN]) [0063] Compounds 1, 2, 3 and 4 were first evaluated for their antiviral activities towards an influenza virus strain A/PR/8/34 (HINI) by CPE inhibition assay on MDCK cells. In the mode of treatment, Compound 1 showed strong inhibitory effect on A/PR/8/34 (HINI) virus-induced CPE in non-toxic concentration with an IC 50 of 18.7 pM and a selection index (SI) of > 11.3 (as shown in Table 3). While, the other three tested M006.03 1.DRF 14 Spec draft v.1 compounds did not exhibit any significant anti-HINI activity (SI < 1 for Compounds 2 to 4). Except for a substitution of a vanilloyl moiety at C-6" of Compound 1 (as shown in Fig. 2), Compound 1 closely resembles to Compound 4 in chemical structure. But their anti-HINI activities were notably different in that Compound 1 displayed extremely potent anti-HINI activity with SI value of > 11.3, while Compound 4 did not possess such bioactivity with SI < 1. This result indicated that a vanilloyl group at C-6" is an indispensable part for anti-HINI activity of Compound 1. Table 3 Anti-HINI virus effects of Compounds 1-4 by CPE inhibition assay TC a, IC a1 Com1pounld SI 1 >210.4 <18.7 >11.3 2 >442.5 >442.5 <1.0 3 >442.5 >442.5 <1.0 4 >384.6 >384.6 <1.0 Ribavirin >819.0 <25.6 >32.0 [0064] 2.4. In vitro anti-influenza virus activities of Compound 1 against other influenza viruses [0065] The anti-influenza effect of Compound 1 was further examined by using CPE assay against a series of both human and avian influenza viruses. As shown in Table 4, Compound 1 exhibited potent antiviral activities at different magnitudes against influenza viruses from human isolates including influenza A [A/PR/8/34 (HINI), A/FM/1/47 (HINI) and A/Aichi/2/68 (H3N2)] and influenza B (B/Lee/1940) subtypes with IC 50 values ranged from 13.4 to 39.8 pM and SI values of 3.7 - 11.4. The inhibitory effects of Compound 1 against influenza A/Aichi/2/68 and B/Lee/1940 viruses were stronger (5.3 and 6.9 folds respectively) than those of the antiviral drug ribavirin, a positive control, while showed similar efficacy towards A/PR/8/34 (HINI) and less inhibitory activity against influenza virus A/FM/1/47 (as shown in Table 4 and Fig. 5). On the contrary, Compound 1 displayed no effect towards three avian influenza virus strains including H6N2 (A/Duck/Guangdong/2009), H7N3 (A/Duck/Guangdong/1994) and H9N2 (A/Chicken/Guangdong/1996) with IC 50 values greater than 138.1 pM and SI < 1 in all M006.03 1.DRF 15 Spec draft v.1 cases. The specific inhibitory effect on human influenza viruses of Compound 1 was noted. Table 4 The effects of Compound 1 against human and avian influenza viruses Virus type and strain IC, (PM) SI 1 Ribavirin 1 Ribavirin A /PR/8/34 (HINI) 24.5+4.5 21.9+1.6 5.8+1.1 47.0±3.4 A /FIM1/47 (HINI) 39.8i11.5 23.3+2.1 3.7+0.9 44.4±4.1 A/Aichi/2/68 (H3N2) 16.3+2.3 86.6+5.0 8.6+1.3 11.9±0.7 A /Duck/Guangdong/2009 (H6N2) >138.1 81.5±3.9 <1.0 12.6+0.6 A /Duck/Guangdong/1994 (H7N3) >138.1 63.8±4.6 <1.0 16.1+1.2 A/Chicken/Guangdong/1996 (H9N2) >138.1 42.3±2.2 <1.0 24.3+1.3 Inf B/Lee/1940 13.4+4.1 92.9±5.5 11.4±3.7 11.1+0.7 ADV3 >37.3 - <1.0 RSV >37.3 - <1.0 [0066] Generally, infection of host cell with human or avian influenza viruses requires specific interaction between cell oligosaccharides containing sialic acid residues and the influenza viral hemagglutinin (Matrosovich M.N. et al., 1997, Ning Z. Y. et al., 2012 and Wang H. et al., 2012). It is widely believed that the receptors containing sialic acid with an a-2, 3-linkage to the penultimate galactose were the receptor for avian influenza viruses, while an a -2, 6-sialic acid -linked receptor was preferred by human influenza viruses (Matrosovich M.N. et al., 1997, Ning Z. Y. et al., 2012 and Wang H. et al., 2012). The specific affinity of Compound 1 to an a -2, 6-sialic acid -linked receptor rather than a -2, 3-sialic acid -linked receptor may interrupt the entry of human influenza viruses into host cells; consequently, the selective inhibiting effect on human influenza viruses of Compound 1 was observed. [0067] 2.5. Selectivity of compound 1 for influenza viruses [0068] In order to gain an insight into selectivity of Compound 1 for human influenza viruses, its antiviral activities against two non-influenza viruses, RSV and ADV3, were also investigated by CPE inhibition assay on HEp-2 cell. As a result (as shown in Table M006.03 1.DRF 16 Spec draft v.1 4), Compound 1 did not show inhibition activity with IC 50 values greater than 37.3 pM and SI < 1 in both cases. These results indicated that Compound 1 has selective and specific inhibitory effects on human influenza viruses. [0069] 3. Conclusion [0070] In this invention, a new lignan glycoside, (+)-pinoresinol 4-0-[6"-O-vanilloyl]-p3 D-glucopyranoside (Compound 1) and two known phenolic compounds, 6-0 vanilloyltachioside (Compound 2) and 6'-O-vanilloylisotachioside (Compound 3) were isolated from the latex of Calotropis gigantea (Asclepiadaceae). The structure of the new compound was elucidated by using spectroscopic and chemical methods. [0071] Compounds 1-3 and (+)-pinoresinol 4-O-p8-D-gluco-pyranoside (Compound 4) were screened for anti-HINI activity by cytopathic effect (CPE) inhibition assay, and compound 1 was further evaluated for in vitro antiviral activities by CPE inhibition assay on Madin-Darby Canine Kidney (MDCK) cell and HEp-2 cell. As demonstrated from the results, Compound 1 showed more potent inhibitory effect against influenza A strain A/Aichi/2/68 and influenza B strain B/Lee/1940 viruses (5.3 and 6.9 folds, respectively) than those of antiviral drug ribavirin, a positive control, while Compound 1 also showed similar efficacy towards A/PR/8/34 (HINI) and less inhibitory activity against A/FM/1/47 with IC 5 0 values ranged from 13.4 to 39.8 pM. However, Compound 1 was inactive towards three subtypes of avian influenza viruses, i.e., A/Duck/Guangdong/2009(H6N2), A/Duck/Guangdong/1 994(H7N3), A/Chicken/Guangdong/1996(H9N2) and two non-influenza viruses, i.e., respiratory syncytial virus (RSV) and adenovirus 3 (ADV3). [0072] In a sharp contrast, the other three compounds (Compounds 2-4) did not show inhibitory activity towards A/PR/8/34 (HINI). An analysis of structure and activity relationship between Compounds 1 and 4 revealed that the presence of a vanilloyl moiety in the sugar moiety of 1 is crucial for its anti-influenza virus activities. This novel lignan glycoside (Compound 1) represents a promising candidate for the research and development of anti-influenza agents. M006.03 1.DRF 17 Spec draft v.1 [0073] The exemplary embodiments of the present invention are thus fully described. Although the description referred to particular embodiments, it will be clear to one skilled in the art that the present invention may be practiced with variation of these specific details. Hence this invention should not be construed as limited to the embodiments set forth herein. [0074] References 1. Abe F., Yamauchi T., Lignan glycosides from Parsonsia laevigata. Phytochemistry. 28 (6), 1737 - 1741. 2. Bhaskara Rama Murti P., Seshadri T. R., 1943. Chemical composition of Calotropis gigantea Part I. wax and resin components of the latex. Proceedings - Indian Academy of Sciences, Section A. 18A, 145 - 159. 3. Deyde V. M., Xu X., Bright R. A., Shaw M., Smith C.B., Zhang Y., Shu Y.L., Gubareva L. V., Cox N. J., and Klimov A. I., 2007. Surveillance of Resistance to adamanthanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196, 249-257. 4. Deyama T., 1983. The constituents of Eucommia ulmoides OLIV. I. Isolation of (+)-Medioresinol Di-0--D-glucopyranoside. Chem. Pharm. Bull. 31, 2993 - 2997 5. Du J., Cross T. A. and Zhou H.X., 2012. Recent progress in structure-based anti influenza drug design. Drug Discov. Today. 17(19/20), 1111-1120. 6. Ehrhardt C., Hrincius E.R., Korte V., Mazur I., Droebner K., Poetter A., Dreschers S., Schmolke M., Planz 0., Ludwig S., 2007. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res. 76, 38-47. 7. Flora of China (FOC): Calotropis gigantea, http://www.efloras.org/florataxon.aspx?flora_id=2&taxon-id=200018512, retrieved date 29 May 2013 M006.03 1.DRF 18 Spec draft v.1 8. Gao H.N., Lu, H.Z., Cao B., Du B., Shang H., Gan J.H., Lu S.H., Yang Y.D., Fang Q., Shen Y.Z., Xi X.M., Gu Q., Zhou X.M., Qu H.P., Yan Z., Li F.M., Zhao W., Gao Z.C., Wang G.F., Ruan LX, Wang W.H., Ye J., Cao H.F., Li X.W., Zhang W.H., Fang X.C., He J., Liang W.F., Xie J., Zeng M., Wu X.Z., Li J., Xia Q., Jin Z.C., Chen Q., Tang C., Zhang Z.Y., Hou B.M., Feng Z.X., Sheng J.F., Zhong N.S., Li L.J., 2013. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 13; 368 (24), 2277-2285. 9. Hsieh C.F., Lo C.W., Liu C.H., Lin S., Yen H.R., Lin T.Y., Horng J.T., 2012. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. J Ethnopharmacol 143(1): 57-67. 10. Hui M.B., Lien E.J., Trousdale M.D., 1994. Inhibition of human adenoviruses by 1-(2'-hydroxy-5'-methoxybenzylidene)amino-3-hydroxyguanidine tosylate. Antiviral Res. 24, 261-273. 11. Knox Y.M., Suzutani T., Yosida I., Azuma M., 2003. Anti-influenza virus activity of crude extract of Ribes nigrum L. Phytother Res. 17, 120-122. 12. Kiyohara H., Ichino C., Kawamura Y., Nagai T., Sato N., Yamada H., Salama M. H. and Abdel-Sattar E., 2012. In vitro anti-influenza virus activity of a cardiotonic glycoside from Adenium obesum (Forssk). Phytochemistry. 19, 111-114. 13. Lhinhatrakul T. and Sutthivaiyakit S., 2006. 19-Nor- and 18,20-Epoxy cardenolides from the Leaves of Calotropis gigantean. J. Nat. Prod. 69, 1249-1251. 14. Ludwig S, Wolff T, Ehrhardt C, et al. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 2004, 561(1-3):37-43. 15. Matrosovich M. N., Gambaryan A. S., Teneberg S., Piskarev V. E., Yamnikova S., Lvov D. K., Robertson J. S., Karisson K. A., 1997. Avian influenza A viruses by recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the HA receptor-binding site. Virology. 233, 224 - 234. M006.03 1.DRF 19 Spec draft v.1 16. Matsunami K., Otsuka H., Kondo K., Shinzato T., Kawahata M., Yamaguchi K., Takeda Y., 2009. Absolute configuration of (+)-pinoresinol 4-0-[6"-O-galloyl]-3-D glucopyranoside, macarangiosides E, and F isolated from the leaves of Macaranga tanarius. Phytochemistry. 70, 1277 - 1285. 17. Miyamoto, D., Hasegawa, S., Sriwilaijaroen, N., Yingsakmongkon, S., Hiramatsu, H., Takahashi, T., Hidari, K., Guo, C., Sakano, Y., Suzuki, T., Suzuki, Y., 2008. Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull. 31, 217-222. 18. Ning Z. Y., Wu X. T., Cheng Y. F., Qi W. B., An Y. F., Wang H., Zhang G. H., Li S. J., 2012. Tissue distribution of sialic acid-linked influenza virus receptors in beagle dogs. J. Vet. Sci. 13, 219 - 222. 19. Par K., Rao P. J., Devakemar C., Rastogi J. N., 1998. A novel Insect antifeedant nonprotein amino acid from Calotropis gigantea. J. Nat. Prod. 61, 102 - 104. 20. Reed L. J., Muench H., 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (3), 493 - 497. 21. Silva M. C. C., Silva A. B., Teixeira F. M., Sousa P. C. P., Rondon T. M. M., Honorio Junior J. E. R., Sampiao L. R. L., Oliveira S. L., Holonda A. N. M. and Vasconcelos S. M. M., 2010. Therapeutic and biological activities of Calotropis procera (Ait.) R. Br. Asian. Pac. J. Trop. Med. 332-336. 22. Sriwilaijareon N., Fukumoto S., Kumagai K., Hiramatsu., Odagiri T., Tashiro M. and Suzuki Y., 2012. Antiviral effects of Psidium guajava Linn. (guava) tea on the growth of clinical isolated HINI viruses: Its role in viral hemagglutination and neuraminidase inhibition. Antiviral res. 94, 139-146. 23. Wang H., Wu X. T., Cheng Y. F., An Y. F., Ning Z. Y., 2012. Tissue distribution of human and avian type sialic acid influenza virus receptors in domestic cat. Acta Vet. Hung. Doi: 10.1556/Avet.2013030. M006.03 1.DRF 20 Spec draft v.1 24. World Health Organization (WHO): http://www.who.int/topics/influenza/en, World Health Organization Web, retrieved date 29 May 2013. 25. Yingsakmongkon S., Miyamoto D., Sriwilaijareon N., 2008. In vitro inhibition of human influenza A virus infection by fruit-juice concentrate of Japanese plum. Biol. Pharm. Bull. 31, 511 - 515. <DocRef#00125742-RM > M006.03 1.DRF 21 Spec draft v.1
Claims (6)
1. A lignan glycoside compound represented by formula (I). OR HOK (I) OMG
2. The lignan glycoside compound of claim 1 wherein R is represented by vanilloyl group represented by formula (II); OH said compound is (+)-pinoresinol 4-0-[6"-O-vanilloyl]-p-D-glucopyranoside and represented by formula (III). OMe M006.031.DRF 22 Spec draft v.1
3. A method of treating influenza comprising administering an effective amount of a lignan glycoside compound to a subject in need thereof; said lignan glycoside compound comprises at least one vanilloyl moiety.
4. The method of claim 3 wherein said lignan glycoside compound is the compound of claim 2.
5. The method of claim 3 wherein said influenza is caused by an influenza virus selected from a group consisting of influenza A strain A/Aichi/2/68, influenza A strain A/PR/8/34, influenza A strain A/FM/1/47 and influenza B strain B/Lee/i 940.
6. A method of isolating said compound of claim 2 comprising the steps of: a) adding 95% ethanol to latex of Calotropis gigantea produce a filterable precipitate mixture; b) said mixture was sonicated at room temperature then centrifuged; c) supernatant from the centrifuge product of step (b) was evaporated under reduced pressure to obtain a light yellowish residue; d) said residue was suspended in H 2 0 and subjected to liquid-liquid partition by adding EtOAc; e) said residue of EtOAc layer was subjected to silica gel CC eluted with the gradient system of CHCl 3 -MeOH-H 2 0 to obtain four fractions of Fr. Ito Fr.4; f) the third fraction, Fr.3, from step (e) was chromatographed over MCI-gel CHIP 20P CC eluted with aqueous MeOH to obtain six sub-fractions of Fr.3-1 to Fr.3-6; g) the fourth sub-fraction, Fr.3-4, from step (f) was loaded to Bondapak Waters® ODS CC using the gradient of MeOH-H 2 0 to obtain seven sub-fractions of Fr.3 4-1 to Fr.3-4-7; h) the fifth sub-fraction, Fr.3-4-5, from step (g) was purified by Silica gel 60 CC eluted with the gradient system of CHCl 3 -MeOH-H 2 0 to obtain eleven sub fractions of Fr.3-4-5-1 to Fr.3-4-5-1 1; and i) the fifth sub-fraction, Fr.3-4-5-5, from step (h) was further purified by MCI-gel CHIP 20P CC using aqueous MeOH to obtain said compound. <DocRef#00125742-RM > M006.03 1.DRF 23 Spec draft v.1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461923229P | 2014-01-03 | 2014-01-03 | |
US61/923,229 | 2014-01-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2014100709A4 true AU2014100709A4 (en) | 2014-07-24 |
Family
ID=51257193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2014100709A Ceased AU2014100709A4 (en) | 2014-01-03 | 2014-06-24 | In Vitro Anti-influenza Virus Activities of a New Lignan Glycoside from the Latex of Calotropis gigantea |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2014100709A4 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945452A (en) * | 2015-04-08 | 2015-09-30 | 富力 | Method for preparing phillygenin glucuronic acid derivative and application thereof |
-
2014
- 2014-06-24 AU AU2014100709A patent/AU2014100709A4/en not_active Ceased
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945452A (en) * | 2015-04-08 | 2015-09-30 | 富力 | Method for preparing phillygenin glucuronic acid derivative and application thereof |
CN104945452B (en) * | 2015-04-08 | 2017-12-05 | 富力 | A kind of preparation method and applications of phillygenol glucuronic acid derivative |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Parhira et al. | In vitro anti-influenza virus activities of a new lignan glycoside from the latex of Calotropis gigantea | |
Jiang et al. | Barbaloin protects against lipopolysaccharide (LPS)-induced acute lung injury by inhibiting the ROS-mediated PI3K/AKT/NF-κB pathway | |
Sharma et al. | Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives | |
Jeong et al. | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities | |
Yang et al. | Antiviral activity of Isatis indigotica root-derived clemastanin B against human and avian influenza A and B viruses in vitro | |
Jeong et al. | Homoisoflavonoids from Caesalpinia sappan displaying viral neuraminidases inhibition | |
Sawai et al. | Anti-influenza virus activity of Chaenomeles sinensis | |
Xing et al. | Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots | |
Ha et al. | Antiviral phenolics from the leaves of Cleistocalyx operculatus | |
AU2009347566B2 (en) | A novel standardized composition, method of manufacture and use in the resolution of RNA virus infection | |
WO2006116656A2 (en) | Compositions comprising triterpene saponins and compounds with functional angeloyl groups for inhibition of venous insufficiency, leg swelling and tumors | |
He et al. | Isolation, structural characterization and neuraminidase inhibitory activities of polyphenolic constituents from Flos caryophylli | |
EP2910563A1 (en) | Triterpene derivative and its anti-influenza use | |
US8476311B2 (en) | Composition for treating influenza A (H1N1) virus and a preparation method therefor | |
Heo et al. | Antiviral activity of Poncirus trifoliata seed extract against oseltamivir-resistant influenza virus | |
KR20190126713A (en) | Composition for preventing or suppressing infection of influenza virus comprising Ginseng berry polysaccharide | |
Chen et al. | Isocorilagin, isolated from Canarium album (Lour.) Raeusch, as a potent neuraminidase inhibitor against influenza A virus | |
Chang et al. | Bioconverted Jeju Hallabong tangor (Citrus kiyomi× ponkan) peel extracts by cytolase enhance antioxidant and anti-inflammatory capacity in RAW 264.7 cells | |
Zhou et al. | Flavonoid glycosides and potential antivirus activity of isolated compounds from the leaves of Eucalyptus citriodora | |
US20080152735A1 (en) | Herbal Extract Having Anti- Influenza Virus Activity and Preparation of Same | |
Ye et al. | Hypolipidemic effect of a novel biflavonoid from shells of Camellia oleifera (Abel.) | |
Kostikova et al. | The antiviral, antiradical, and phytochemical potential of dry extracts from Spiraea hypericifolia, S. media, and S. salicifolia (Rosaceae) | |
CA2982200C (en) | Phillygenin glucuronic acid derivative as well as preparation method and application thereof | |
Sánchez-Roque et al. | The flavonoid fraction from Rhoeo discolor leaves acting as antiviral against influenza A virus | |
Hayashi et al. | Evaluation of fractions and isolated polysaccharides from Sasa veitchii for their preventive effects on influenza A virus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |